S3V Vascular Technologies Ltd - Unlisted Shares
Fundamentals
- Current Price
- ₹575
- Market Cap
- ₹1,102.77 Cr
- ISIN
- INE0HGT01012
- Face Value
- ₹10
- EPS
- -1.66
- P/B Ratio
- 7.83
- Book Value
- ₹73.39
- Debt / Equity Ratio
- 0.18
Key Financials
Profit & Loss
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue from Operations | 14.93 | 18.9 | 20.91 | 16.13 |
| Growth % | -21.01% | -9.61% | 29.63% | 16.29% |
| Operating Expenses | 12.58 | 15.29 | 15.32 | 12.4 |
| Growth % | -17.72% | -0.20% | 23.15% | 16.26% |
| Operating Profit | 2.35 | 3.61 | 5.59 | 3.69 |
| Op. Profit Margin % | 15.74% | 19.10% | 26.73% | 22.88% |
| Other Income | 0.23 | 0.08 | 0.1 | 0 |
| Finance Costs | 3.56 | 1.31 | 1.41 | 1.62 |
| Depreciation | 2.07 | 1.73 | 1.48 | 1.41 |
| Exceptional items | 0 | 0 | 0 | 1.09 |
| Profit Before Tax | -3.1 | 0.6 | 2.8 | 2.2 |
| Tax | 0.14 | 0.09 | 0.12 | 0.44 |
| Tax % | -4.59% | 13.85% | 4.27% | 20.37% |
| Profit After Tax | -3.2 | 0.6 | 2.7 | 1.7 |
| Growth % | -669.64% | -79.18% | 56.40% | -176.44% |
| PAT % | -21.37% | 2.96% | 12.86% | 10.66% |
Company Financials
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Equity Capital | 19.2 | 13.2 | 13.0 | 12.9 |
| Reserves | 121.6 | 25.8 | 21.9 | 16.9 |
| Total Equity | 140.8 | 39.1 | 34.9 | 29.7 |
| Financial Laibilities | 11.2 | 21.1 | 8.9 | 11.21 |
| Provisions | 0.4 | 0.3 | 0.0 | 0.0 |
| Other Non-Current Liabilities | 3.4 | 5.3 | 4.6 | 4.3 |
| Total NC Liabilities | 15.0 | 26.8 | 13.6 | 15.5 |
| Short term Borrowings | 14.1 | 8.6 | 11.0 | 7.3 |
| Other Current Liabilities | 7.8 | 5.2 | 4.2 | 10.2 |
| Total Current Liabilities | 21.9 | 13.8 | 15.2 | 17.5 |
| Equity + Liabilities | 177.6 | 79.6 | 63.6 | 62.7 |
| Fixed Assets (incl. WIP) | 25.8 | 20.3 | 18.7 | 18 |
| Other Non Current Assets | 17.9 | 15.2 | 4.1 | 7.7 |
| Total NC Assets | 43.6 | 35.5 | 22.8 | 26.1 |
| Trade Receivables | 37.1 | 34 | 31.6 | 25.1 |
| Cash & Cash Equivalents | 77 | 1.6 | 0.8 | 3.3 |
| Other Current Assets | 19.9 | 8.6 | 8.4 | 8.3 |
| Total Current Assets | 134.0 | 44.2 | 40.8 | 36.7 |
| Total Assets | 177.6 | 79.6 | 63.6 | 62.7 |
Shareholding Pattern
- N G Badari Narayan
- 16.76%%
- Kalindhi Narayan
- 8.43%%
- Vijaya Gopal Nagaragadde
- 6.12%%
- Vishnu Shreyas
- 5.05%%
- Srivatsa Sarang
- 4.69%%
- L&T Welfare Company Limited (CCPS)
- 7.41%%
- Mahima Stocks Private Limited (CCPS)
- 5.63%%
- Others
- 45.91%%
Strengths & Weaknesses
Strengths
- Strong Investor Confidence: The company is backed by prominent investors, including Mr. A.M. Naik (former Chairman of L&T) and Mr. Madhusudan Kela and raised around 300 Cr from such investors in their ‘Series B’ round.
- Government Backed: S3V is in process to build India's First Neuro-Intervention Integrated Manufacturing Plant for Stroke Treatment and is backed by the Technology Development Board (TDB), Department of Science and Technology (DST).
- Industry Growth: Industry experts project the Indian medical devices market to reach $50 billion by 2025, growing at an impressive annual rate of 15 to 20 percent, outpacing the global industry.(Source:Economic Times)
- Business Growth: The company aims to integrate these devices into government reimbursement programs such as Ayushman Bharat, thereby unlocking a domestic market estimated at 2 Billion USD
Weaknesses
- Regulatory & Clinical Approval Risks: The company is currently initiating CE certification and seeking USFDA approval for its next-generation products, including neuro-intervention devices. Delays or failures in achieving these certifications could severely hinder market access.
- High Capital Requirements: The company relies on venture capital, angel networks, and government support (TDB) for funding. Sustaining research, development, and trials without immediate, large-scale revenue could pose financial risk.
About S3V Vascular Technologies Ltd
S3V Vascular Technologies is a medical device company based in India and incubated at “Indian School of Business (ISB)”. It focuses on developing and manufacturing advanced medical devices to treat cardiovascular diseases (conditions affecting the heart and blood vessels). S3V Vascular Technologies is set to become the first Indian company to indigenously design and manufacture the complete suite of neuro-intervention devices, including microcatheters, aspiration catheters, guidewires, and stent retriever systems in an upstream integrated facility. The company also intends to file patents for critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and several advanced process technologies
Board of Directors
- Vijaya Gopal Nagaradagadde - Managing Director
- Badari Narayan Nagarada Gadde - Whole Time Director
- Nagarada Gadde Vishnu Shreyas - Whole Time Director
- Veeresham Ciddi - Independent Director
- Prithi Sureka Mummidi - Independent Director
- Govindan Ramaswamy - Independent Director
- Mr. Narayan Kalindhi - Non-Independent Director
- Mr. Narendra Kumar Srisrimal - Non-Independent Director
- Mr. Venkateswara Gowtama Mannava - Non-Independent Director
- Mr. Dip Kishore - Non-Independent Director
Senior Management
- Badari Narayan Nagarada Gadde - Chief Executive Officer
- Nagarada Gadde Vishnu Shreyas - Chied Financial Officer
- Mr. Anuj Mehta - Company Secretary
Frequently Asked Questions
- Is there any lock in period for S3V Vascular Technologies Ltd unlisted shares?
- The lock-in period for S3V Vascular Technologies Ltd Unlisted Shares differs based on the investor category, as per SEBI regulations:
●Venture Capital Funds and Foreign Venture Capital Investors (FVCIs): A lock-in period of 6 months from the date of acquisition of the shares.
●Alternative Investment Funds – Category II (AIF-II): No lock-in period is applicable.
●Other investors (including retail investors, high net-worth individuals (HNIs), and body corporates): A lock-in period of 6 months from the date of IPO listing of S3V Vascular Technologies Ltd .
These norms were introduced by SEBI in August 2021, reducing the earlier lock-in requirement from one year to six months. The change was aimed at improving liquidity and encouraging investor participation in companies preparing for public listings. Since then, interest in pre-IPO investments has increased, with investors exploring opportunities to participate in companies ahead of their potential listing. - How much long term capital gains tax do I have to pay on S3V Vascular Technologies Ltd unlisted shares?
- Long-Term Capital Gains (LTCG) on Unlisted Shares in India arise when such shares are sold after being held for a period of more than two years. The key aspects of LTCG taxation on S3V Vascular Technologies Ltd unlisted shares are outlined below:
1. Tax Rate
Earlier, LTCG on unlisted shares was taxed at 20% with indexation benefits. However, as per Union Budget 2024, the tax structure has been revised. For transfers made on or after 23rd July 2024, LTCG on unlisted shares is taxed at a flat rate of 12.5%.
2. Indexation Benefit
Previously, investors could avail indexation benefits to adjust the purchase price for inflation, thereby reducing taxable gains. This indexation benefit has been removed under Budget 2024 for unlisted shares transferred on or after 23rd July 2024
. 3. Importance for Investors
Understanding LTCG taxation is important for both retail investors and High Net-Worth Individuals (HNIs), as it directly impacts investment returns, exit planning, and overall tax strategy.
4. Calculation Method
For eligible transactions after 23rd July 2024, LTCG will be calculated at a flat tax rate of 12.5% on the capital gains, without indexation.
5. Applicability
LTCG tax is applicable when unlisted shares are held for more than 24 months before being sold.
6. Relevance
These tax provisions are particularly relevant for investors in the unlisted share market who are considering exiting their investments after a long-term holding period. - How do I start investing in S3V Vascular Technologies Ltd unlisted shares through InCred Money?
- Buying S3V Vascular Technologies Ltd Unlisted Shares on InCred Money is quick, seamless, and fully digital.
Step 1: Create Your Account
Sign up using your mobile number and email ID. Complete your KYC by submitting your PAN, Aadhaar, bank account, and demat account details. Once submitted, your KYC is reviewed and approved.
Step 2: Select & Buy Shares Browse and select S3V Vascular Technologies Ltd from our Unlisted Shares list and place your order.
Step 3: Share Transfer Based on the settlement period for the shares noted on the platform, the purchased shares are transferred and reflected in both your InCred Money portfolio and your demat account. - What documents are needed to invest in S3V Vascular Technologies Ltd unlisted shares?
- To invest in S3V Vascular Technologies Ltd Unlisted Shares on InCred Money, you need to complete your The lock-in period for S3V Vascular Technologies Ltd Unlisted Shares differs based on the investor category, as per SEBI regulations:
●Venture Capital Funds and Foreign Venture Capital Investors (FVCIs): A lock-in period of 6 months from the date of acquisition of the shares.
●Alternative Investment Funds – Category II (AIF-II): No lock-in period is applicable.
●Other investors (including retail investors, high net-worth individuals (HNIs), and body corporates): A lock-in period of 6 months from the date of IPO listing of S3V Vascular Technologies Ltd .
These norms were introduced by SEBI in August 2021, reducing the earlier lock-in requirement from one year to six months. The change was aimed at improving liquidity and encouraging investor participation in companies preparing for public listings. Since then, interest in pre-IPO investments has increased, with investors exploring opportunities to participate in companies ahead of their potential listing.KYC verification by submitting the following documents:
●PAN Card
●Aadhaar Card
●Bank account details
●Demat account details
Once your KYC is successfully completed and approved, you can start investing in unlisted shares on the platform.